SCHEMBL6494078

SCHEMBL6494078

CCOC(=O)c1nc(C)[nH]c1-c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 1/20 0.56
KDM4E B2RXH2 5/20 0.55
HPGD P15428 4/20 0.55
ALDH1A1 P00352 4/20 0.55
LMNA P02545 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
GAA P10253 2/20 0.55
MAPT P10636 2/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
KMT2A Q03164 3/20 0.53
HSD17B10 Q99714 2/20 0.53
MDM2 Q00987 3/20 0.53
CHEK1 O14757 1/20 0.49
EGFR P00533 1/20 0.49
KDR P35968 1/20 0.49
MEN1 O00255 2/20 0.49
MAPK10 P53779 1/20 0.49
GABRA2 P47869 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28582964 0.87 TARBP2 (0.54) TARBP2KDM4EHPGDALDH1A1LMNA
SCHEMBL9050658 0.84 ALOX5 (0.56) TARBP2HPGDALDH1A1SMN1; SMN2MAPT
SCHEMBL14953548 0.83 TARBP2 (0.51) TARBP2KDM4EHPGDALDH1A1LMNA
SCHEMBL9049053 0.82 KDM4E (0.50) TARBP2KDM4EHPGDALDH1A1LMNA
SCHEMBL5763126 0.81 KDM4E (0.58) KDM4EHPGDALDH1A1LMNASMN1; SMN2
SCHEMBL28914603 0.79 AR (0.54) TARBP2ALDH1A1LMNAGAAMAPT
SCHEMBL7989862 0.79 AR (0.54) TARBP2ALDH1A1LMNAGAAMAPT
SCHEMBL7995767 0.79 KDM4E (0.49) TARBP2KDM4EHPGDALDH1A1LMNA
SCHEMBL13174731 0.79 MAPT (0.54) TARBP2KDM4EHPGDALDH1A1LMNA
SCHEMBL24427668 0.78 KDM4E (0.54) KDM4EHPGDALDH1A1SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AVENTIS PHARMA S.A. (FR) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AHR, ARNT, MYC TARBP2 3349/4885KDM4E 1246/4885HPGD 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.